MiR-451a attenuates hepatic steatosis and hepatitis C virus replication by targeting glycerol kinase

Swagata Majumdar1, Deeya Roy Chowdhury1, Bidhan Chandra Chakraborty2

  • 1Centre for Liver Research, School of Digestive and Liver Diseases, Institute of Post Graduate Medical Education and Research, Kolkata, West Bengal, India.

PubMed
Abstract

Insights

Downregulation of miR-451a in chronic hepatitis (CH) leads to lipid accumulation by increasing glycerol kinase (GK) expression. Restoring miR-451a may treat CHC by reducing lipid buildup and viral replication.

Area of Science:

  • Molecular biology
  • Hepatology
  • Virology

Background:

  • Lipotoxicity contributes to fatty liver progression in chronic hepatitis (CH).
  • MicroRNAs (miRNAs) regulate lipid metabolism, but direct targets remain elusive.
  • miR-451a is identified as a downregulated miRNA in CH with potential impact on lipid metabolism.

Purpose of the Study:

  • To characterize the role of downregulated miR-451a in chronic hepatitis.
  • To identify direct targets of miR-451a within the lipid metabolism pathway.
  • To investigate the therapeutic potential of miR-451a supplementation in CHC.

Main Methods:

  • Analysis of liver tissues and blood from CHC/CHB patients and controls.
  • In vitro studies using Huh7 and SNU449 cell lines.
  • Gene and protein expression analysis (qRT-PCR, immuno-blot), lipid quantification (Oil Red O, colorimetric/fluorometric assays), target prediction, pathway analysis, 3'UTR-Luciferase assay, and Co-immunoprecipitation.

Main Results:

  • miR-451a was downregulated in progressive CHC and CHB.
  • Glycerol kinase (GK) was identified and confirmed as a direct target of miR-451a.
  • HCV infection suppressed miR-451a, increasing GK, SREBP1, and downstream lipogenic enzymes, leading to lipid accumulation and hypocholesterolemia; restoring miR-451a reversed these effects and suppressed HCV replication.

Conclusions:

  • Downregulation of miR-451a contributes to altered hepatic lipid profiles in HCV/HBV infection.
  • miR-451a restricts GK and SREBP1 expression in the triglyceride biosynthesis pathway.
  • miR-451a supplementation shows potential as a therapeutic strategy for CHC.